Introduction
============

There has been increasing interest in the application of ultrasmall ferrite nanoparticles (UFNPs) in nanomedicine due to their uniquely appealing magnetic resonance (MR) T~1~ contrast effects [@B1]-[@B8]. In comparison with commercial Gd-based T~1~ contrast agents, UFNPs with sizes smaller than 5 nm have exhibited enhanced r~1~ relaxivities [@B8] and improved biosafety [@B9]. Previous studies have indicated that the *in vitro* T~1~ contrast ability of the UFNPs is closely correlated with their material parameters, such as size [@B1], [@B5], [@B10], composition [@B7], [@B11], [@B12] and surface chemistry [@B10], [@B13]. To achieve efficient MR T~1~ contrast agents, efforts have been devoted to chemically tailoring the material parameters of UFNPs to maximizing the r~1~ relaxivity. However, enhancement of the *in vitro* r~1~ relaxivity alone is inadequate for generating high- performance UFNP-based MR T~1~ contrast agents. Multiple biological steps are involved in the systemic delivery of contrast agents to biological targets, and the biosafety of the agents can influence their *in vivo* T~1~ contrast efficacies [@B9], [@B14]-[@B18]. In fact, both experimental results and clinical data have verified that the *in vivo* efficacies of contrast agents are determined by a complex interplay of the *in vitro* T~1~ relaxivity, the *in vivo* nano-bio interactions and their toxicity. As a result, their blood circulation, biodistribution and toxicity effects are important factors to consider along with their r~1~ relaxivity [@B19]-[@B21]. Significantly, a variation in any material parameter can alter all related factors, resulting in an unpredictable *in vivo* T~1~ contrast efficacy [@B16]. For example, in addition to the T~1~ relaxivity dependence, the proper size selection of UFNPs can prolong their blood circulation times, which in turn leads to high accumulation in targeting tissue and greater *in vivo* contrast efficacy [@B1], [@B7]. Therefore, understanding the correlations between the material parameters of UFNPs and their *in vitro* T~1~ relaxivities, *in vivo* nano-bio interactions and biosafety is of importance for translating UFNPs into clinical applications.

Among the various chemically tunable material parameters of UFNPs, the UFNP composition has been shown to have a significant impact on the T~1~ relaxivities [@B22]. In particular, ultrasmall manganese ferrite nanoparticles (UMFNPs) can possess a larger r~1~ relaxivity (up to 1.7 times greater) than that of maghemite nanoparticles of the same size. A similar composition dependence of the T~2~ relaxivity has also been reported for large-sized manganese ferrite nanoparticles [@B23]. Moreover, higher particle accumulation in the liver has been found for UMFNPs due to Mn^2+^ doping [@B7], which suggests that the UMFNPs have a unique compositional effect on the *in vivo* nano-bio interactions. In addition, the release of Mn^2+^ may potentially increase the toxicity, which should be optimized [@B24]. However, the interplay of the Mn^2+^ composition and the *in vitro* T~1~ relaxivity, *in vivo* nano-bio interactions and toxicity remains unclear, despite UMFNPs being considered potential MRI T~1~ contrast agents for liver-specific MRI.

In this study, we investigated *in vivo* T~1~ contrast efficacy of composition-tunable UMFNPs to address the concerns of the tunability of*in vitro* T~1~ relaxivities, *in vivo* nano-bio interactions and toxicities of UFNPs. Mn~x~Fe~3-x~O~4~ nanoparticles (3 nm, x = 0.32, 0.37, 0.75, 1, 1.23 and 1.57) were used as a model system to assess the*in vivo* liver-specific contrast efficacy of UMFNPs in mice. The surface functionalization was optimized in terms of the colloidal stability and T~1~ enhancement ability using phosphorylated mPEG with different molecular weights. The compositional dependence of their *in vitro* T~1~ relaxivities, pharmacokinetic behaveiors and biosafety characteristics were systematically evaluated. While Mn~0.75~Fe~2.25~O~4~ exhibited the largest r~1~ relaxivity value of 10.35 mM^-1^s^-1^, the greatest MRI signal enhancement (ΔSNR) of the liver has been obtained by using Mn~1.57~Fe~1.43~O~4~ due to its high liver accumulation. However, high Mn doping concentrations (x = 1.23 and 1.57) simultaneously induced significant cytotoxicity. The comprehensive results indicated that Mn~x~Fe~3-x~O~4~ nanoparticles with Mn-doping concentrations between 0.75 and 1 can exhibit high*in vivo* liver-specific contrast efficacy. This work aims to provide a clear relationship between the compositional characteristics and the *in vivo* T~1~ contrast efficacy of UMFNPs. The results obtained from the current work may provide guidance for the chemical design and preclinical assessment of UFNP-based MR T~1~ contrast agents and facilitate their clinical translation.

Materials and Methods
=====================

Materials
---------

Absolute ethanol, methanol, hexane, ferric chloride hexahydrate (\> 99.0%), manganese chloride tetrahydrate (\> 99.0%), sodium hydroxide (\> 96%), tetrahydrofuran (\> 99.0%), chloroform (\> 99.0%) were used as received. Benzyl ether (98%), oleic acid (90%), oleyl alcohol (65.0%) and Poly (ethylene glycol) methyl ether (flakes, average Mn \~1,000, \~2,000 and \~5,000) were purchased from Aldrich Chemical Co. Erucic acid was purchased from Aladdin Industrial Corporation.

Synthesis of 3 nm Mn~x~Fe~3-x~O~4~ Nanoparticles
------------------------------------------------

The iron-eruciate and manganese-oleate precursors were synthesized using previously reported procedures [@B7]. Mn~x~Fe~3-x~O~4~ nanoparticles (3 nm) were prepared by a general method for the dynamic simultaneous thermal decomposition (DSTD) of the precursors. A typical synthesis of the Mn~0.75~Fe~2.25~O~4~ nanoparticles is briefly described as follows: 1.4 g (1.3 mmol) of the iron-eruciate complex, 0.57 g (2 mmol) of oleic acid, 0.62 g (1 mmol) of the Mn-oleate complex, and 1.61 g (6 mmol) of oleyl alcohol were dissolved in 10 g of benzyl ether. The reaction mixture magnetically stirred under a flow of argon. The reaction mixture was heated to 265 °C with a constant rate of 5 °C/min, and the kept that temperature for 30 min. The resulting solution containing the nanoparticles was then rapidly cooled to room temperature. A black powder was precipitated by the addition of ethanol to the reaction mixture and was then isolated by centrifugation. The isolated UMFNPs were dispersed in hexane for further use. UMFNPs with different Mn doping levels were prepared by mixing different ratios of the precursor under identical conditions. Detailed reaction parameters are summarized in Table [1](#T1){ref-type="table"}.

Preparation of phosphorylated mPEG coated Mn~x~Fe~3-x~O~4~ nanoparticles
------------------------------------------------------------------------

Phosphorylated mPEG was synthesized by reacting POCl~3~ with mPEG as previously reported [@B25]. In a typical process, 10 mg of Mn~x~Fe~3-x~O~4~ nanoparticles and 50 mg of phosphorylated mPEG were transferred into 10 mL of chloroform. Next, the mixture was shaken continuously over a period of 5 h to remove the chloroform and obtain functionalized UMFNPs. Finally, 5 ml of water was added to redisperse the nanoparticles, and passed through a 0.22 µm syringe filter and stored at 4 °C until use.

Characterization
----------------

X-ray powder diffraction studies patterns were obtained with a Bruker D8 Advanced Diffractometer System equipped with Cu/Kα radiation (λ = 1.5418 Å). Transmission electron microscopy (TEM) images were obtained on a field-emission transmission electron microscope (Tecnia G2 F20 S-Twin, FEI, operated at 200 kV). The mean particle sizes were obtained from digital TEM images by counting more than 200 particles. Magnetic properties studies were carried out using a superconducting quantum interference device (SQUID) magnetometer (MPMS- XL-7) with the magnetic field up to 3 T. The hydrodynamic diameters of the UMFNPs were measured by Malvern Zetasizer nano-ZS dynamic light scatting (DLS) instrument. The metal elemental analyses of the samples were performed on inductively coupled plasma atomic emission spectroscopy (ICP-AES) and ICP-MS (PerkinElmer SCIEX, ELAN DRC-e).

Relaxivity Measurements
-----------------------

MR relaxivities of UMFNPs were carried out on an MRI scanner with a head coil at 3 T (Siemens Medical Solutions, Germany). The parameters for T~1~ measurement were set as: echo time (TE) = 19 ms, repetition time (TR) = 4000 ms, and TI = 25, 50, 100, 200, 300, 400, 500, 700, 1000, 1500, 2500, 3500 ms, respectively. For T~2~ relaxivity measurements, the parameters were set as: repetition time (TR) = 5000 ms and echo time (TE) = 13, 30, 92, 113, 141, 170, 198, 210, 240, 278, 322 ms.

MR imaging of liver*in vivo*
----------------------------

The MR images were acquired on a 3.0 T clinical MRI instrument (Siemens Trio). UMFNPs (3 mg \[Fe+Mn\]/kg) were injected into the mice for liver imaging. T~1~-weighted MR images of their livers were obtained at designed time points. The detailed parameters for T~1~ imaging were set as follows: field of view (FOV) = 40 × 80 mm^2^; flip angle (FA) = 120; slice thickness = 3.0 mm; TR = 485 ms; TE = 10 ms; number of excitations (NEX) = 12. *In vivo* experiments were carried out according to protocol approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University.

Biodistribution and Pharmacokinetics Studies
--------------------------------------------

Balb/c mice were injected intravenously with the Mn~x~Fe~3-x~O~4~ nanoparticles at a dose of 3 mg \[Fe+Mn\]/kg mouse body weight to evaluate the biodistribution of the nanoparticles. The mice were sacrificed at 3 h and 24 h post injection (p.i.). The organs of interest (brain, lung, heart, kidney, spleen and liver) were harvested, weighed and quantified using ICP-MS. To determine the pharmacokinetic parameters, mice were injected with Mn~x~Fe~3-x~O~4~ nanoparticles and blood samples were collected at 2 min, 5 min, 10 min, 30 min, 1 h, 3 h, 5 h, 8 h, 12 h, and 24 h p.i. and quantified using ICP-MS. The pharmacokinetic parameters were calculated based on a two-compartment open model.

Results and Discussion
======================

Synthesis of composition tunable UMFNPs
---------------------------------------

The Mn~x~Fe~3-x~O~4~ nanoparticles were synthesized *via* a DSTD method [@B7]. The Mn content (x = 0.32, 0.37, 0.75, 1, 1.23 and 1.57) in the UMFNPs could be controlled by changing the ratios of the precursors. Figure [1](#F1){ref-type="fig"}a-f shows the TEM images of as-prepared Mn~x~Fe~3-x~O~4~ nanoparticles with different Mn content. All samples show a uniform particle size of 3 nm with narrow size distributions (\< 4%) (Figure [S1](#SM0){ref-type="supplementary-material"}). The corresponding high-resolution TEM (HRTEM) images are shown in the inset of Figure [1](#F1){ref-type="fig"}a-f, revealing the high crystallinities of these particles. The lattice spacing distances are found to be 2.12 Å, 2.45 Å, 2.56 Å, 2.45 Å, 2.12 Å and 3.01 Å, which correspond to the (400), (222), (311), (222), (400) and (220) planes, respectively, of the inverse spinel phase of manganese ferrite. Figure [1](#F1){ref-type="fig"}g shows the powder X-ray diffraction (XRD) patterns of the as-synthesized ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. The position of all diffraction peaks matches well with the standard manganese ferrite power diffraction data (JCPDS card no. 10-0319). The ICP-AES elemental analysis revealed the tunable-ratios of Mn:Fe in Mn~x~Fe~3-x~O~4~ can to be 0.32:2.68, 0.37:2.63, 0.75:2.25, 1:2, 1.23:1.77 and 1.57:1.43, which are consistent with the results measured by using energy dispersive X-ray spectroscopy (EDS; Figure [S2](#SM0){ref-type="supplementary-material"} and Table [S1](#SM0){ref-type="supplementary-material"} in the [Supporting Information](#SM0){ref-type="supplementary-material"}). The as-prepared Mn~x~Fe~3-x~O~4~ nanoparticles were further analyzed by X-ray photoelectron spectroscopy (XPS) (Figure [1](#F1){ref-type="fig"}h and [1](#F1){ref-type="fig"}i). The binding energies at 711.9 and 725.8 eV for Mn~0.32~Fe~2.68~O~4~, 711.0 and 724.3 eV for Mn~0.37~Fe~2.63~O~4~, 711.8 and 724.7 eV for Mn~0.75~Fe~2.25~O~4~, 711.8 and 725.5 eV for MnFe~2~O~4~, 710.9 and 725.1 eV for Mn~1.23~Fe~1.77~O~4~, and 711.2 and 724.8 eV for Mn~1.57~Fe~1.43~O~4~ are attributed to Fe 2p3/2 and Fe 2p1/2 referred to Fe^3+^, respectively. The photoelectron peaks at binding energies of Mn 2p3/2 and Mn 2p1/2 were 642.6 and 654.4 eV for Mn~0.32~Fe~2.68~O~4~, 642.0 and 653.9 eV for Mn~0.37~Fe~2.63~O~4~, 642.4 and 654.5 eV for Mn~0.75~Fe~2.25~O~4~, 642.1 and 653.9 eV for MnFe~2~O~4~, 641.8 and 653.7 eV for Mn~1.23~Fe~1.77~O~4~, and 641.6 and 653.2 eV for Mn~1.57~Fe~1.43~O~4~, respectively (Table [S2](#SM0){ref-type="supplementary-material"}). The peak positions of Fe 2p and Mn 2p are consistent with previously reported values for Fe^3+^ and Mn^2+^ [@B7], [@B23], [@B26]. With increasing Mn^2+^, the intensities of the Fe 2p peaks decrease, and those of the Mn 2p peaks increase, which is consistent with the literature results [@B27]. These data suggest that 3 nm Mn~x~Fe~3-x~O~4~ nanoparticles, where x = 0.32, 0.37, 0.75, 1, 1.23 and 1.57, were successfully synthesized by the DSTD method.

Magnetic characterization
-------------------------

The magnetic properties of UMFNPs are strongly associated with their MR relaxivity properties. The magnetic properties of these Mn~x~Fe~3-x~O~4~ nanoparticles were measured using a superconducting quantum interference device (SQUID) with the field up to 3 T. Figure [2](#F2){ref-type="fig"}a shows the field-dependent magnetization (M-H) curves of the ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles at 300 K. The coercivity and remanence are negligible at room temperature for all these samples, indicating superparamagnetic behavior. The variations in magnetization as a function of the Mn-doping concentration are presented in Figure [2](#F2){ref-type="fig"}b. The magnetizations at 3 T are 21.78, 31.07, 26.92, 25.59, 10.69, and 8.20 emu/g for the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~, MnFe~2~O~4~, Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles, respectively. The magnetization was found to initially increase by up to 42% with the increase of x up to 0.37. Metal ferrite nanoparticles has a spinel structure constructed by face-centered cubic packed lattice of oxygen atoms with the tetrahedral sites and octahedral sites [@B28], [@B29]. It is well known that MnFe~2~O~4~ has a mixed spinel structure with the manganese ions predominantly occupying tetrahedral sites. Mn^2+^ has five unpaired electrons, which is the same number as in Fe^3+^, and one more than in Fe^2+^. When an external magnetic field is applied, the magnetic spins of the O~h~ sites align parallel to the direction of the external magnetic field, but those of the T~d~ sites align antiparallel to the field. For Mn~x~Fe~3-x~O~4~ nanoparticles with small x values, the Mn^2+^ dopant can replace Fe^2+^ to give a magnetic moment of (4+x) μ~B~ (Bohr magneton) per formula unit, resulting in an enhanced magnetic moment in comparison with \[Fe^3+^\]~Td~\[Fe^2+^Fe^3+^\]~Oh~O~4~. However, as the doping level further increases, the magnetization gradually decreases to 8.20 emu/g (x = 1.57) due to the weakening of the T~d~-O~h~ interaction when Fe^3+^ is replaced by Mn^2+^ in the T~d~ site [@B30]-[@B32]. Similar results have been observed in large-sized manganese ferrite nanoparticles [@B23], [@B31].

Surface modification of the Mn~x~Fe~3-x~O~4~ nanoparticles
----------------------------------------------------------

Appropriate surface coatings for Mn~x~Fe~3-x~O~4~ nanoparticle-based contrast agents are necessary for improved dispersibilities and T~1~ contrast abilities. Stoichiometric MnFe~2~O~4~ nanoparticles were modified by various mPEG with molecular weights of 1000, 2000 and 5000 g/mol followed by evaluation of their colloidal stabilities and *in vitro* T~1~ relaxivities. Figure [3](#F3){ref-type="fig"}a-c shows the hydrodynamic sizes of the MnFe~2~O~4~ nanoparticles modified with mPEG1000, mPEG2000 and mPEG5000, respectively. The hydrodynamic sizes in deionized water are seen to be 8.74 nm for MnFe~2~O~4~\@mPEG1000, 9.36 nm for MnFe~2~O~4~\@mPEG2000 and 9.87 nm for MnFe~2~O~4~\@mPEG5000. No observable aggregation could be seen under the optical microscope as shown in the insets of Figure [3](#F3){ref-type="fig"}a-c. Figure [3](#F3){ref-type="fig"}d-f shows the time-dependent curves for the hydrodynamic sizes of the mPEG-modified MnFe~2~O~4~ nanoparticles. It can be seen that MnFe~2~O~4~\@mPEG1000 and MnFe~2~O~4~\@mPEG2000 do not show any significant changes in their hydrodynamic sizes after 10 days of incubation in aqueous media at room temperature, while the hydrodynamic size of MnFe~2~O~4~\@mPEG5000 exhibits a significant increase after the 2^nd^ day. The thermogravimetric analysis (TGA) results (Figure [S3](#SM0){ref-type="supplementary-material"} and Table [S3](#SM0){ref-type="supplementary-material"}) indicate that the surface density of MnFe~2~O~4~\@mPEG5000 was much less than those of MnFe~2~O~4~\@mPEG1000 and MnFe~2~O~4~\@mPEG2000 for the same preparation procedures. This may result in the mPEG5000-coated nanoparticles having poor aqueous stability and dispersibility. The results imply that the MnFe~2~O~4~ nanoparticles modified by mPEG1000 and mPEG2000 can achieve excellent colloidal stabilities compared to MnFe~2~O~4~\@mPEG5000. The effects of the surface ligands of the MnFe~2~O~4~ nanoparticles on their MR relaxivities was further evaluated on a clinical 3 T MRI scanner at room temperature. A series of aqueous solutions of the nanoparticles with different \[Fe+Mn\] concentrations were prepared. Figure [3](#F3){ref-type="fig"}g shows the T~1~-weighted MR images of MnFe~2~O~4~\@mPEG1000, MnFe~2~O~4~\@m PEG2000 and MnFe~2~O~4~\@mPEG5000 at different \[Fe+ Mn\] concentration. All of the samples with higher concentration produce brighter images, indicating that the MnFe~2~O~4~\@mPEG1000, MnFe~2~O~4~\@mPEG2000 and MnFe~2~O~4~\@mPEG5000 samples can effectively shorten T~1~ relaxation time of the water protons. However, MnFe~2~O~4~\@mPEG 1000 exhibits brighter images at all designated \[Fe+Mn\] concentrations in comparison with MnFe~2~O~4~\@mPEG2000 and MnFe~2~O~4~\@mPEG5000. The r~1~ relaxivities of the MnFe~2~O~4~\@mPEG1000, MnFe~2~O~4~\@mPEG2000 and MnFe~2~O~4~\@mPEG5000 samples were 10.21, 8.46, and 8.26 mM^-1^s^-1^, respectively (Figure [3](#F3){ref-type="fig"}h). The r~2~ relaxivities of MnFe~2~O~4~\@mPEG1000, MnFe~2~O~4~\@mPEG2000 and MnFe~2~O~4~\@mPEG5000 were 21.27, 21.52, and 38.64 mM^-1^s^-1^, respectively (Figure [S4](#SM0){ref-type="supplementary-material"}b). Figure [3](#F3){ref-type="fig"}i shows the r~1~ and the r~2~/r~1~ curves of the MnFe~2~O~4~ samples with different mPEG coatings. The MnFe~2~O~4~\@mPEG1000 sample exhibits the highest r~1~ relaxivity and the lowest r~2~/r~1~ value of the three samples, indicating that mPEG1000 is the optimal coating for the Mn~x~Fe~3-x~O~4~ nanoparticles. Thus, mPEG1000 was used to modify the Mn~x~Fe~3-x~O~4~ nanoparticles to further investigate their *in vivo* T~1~ contrast efficacy.

The*in vitro* T~1~ contrast ability of the ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles
------------------------------------------------------------------------------------

*In vitro* T~1~ contrast ability refers to the r~1~ relaxivity, which is the efficiency of a millimole of Mn~x~Fe~3-x~O~4~ nanoparticles for enhancing the relaxation rate of water protons [@B33]. To determine the influence of the Mn-doping concentration on the r~1~ relaxivity, the relaxometric properties of the Mn~x~Fe~3-x~O~4~ nanoparticles were measured. 3 nm Mn~x~Fe~3-x~O~4~ nanoparticles with different Mn-doping levels (x = 0.32, 0.37, 0.75, 1, 1.23, 1.57) were modified with mPEG 1000 and dispersed in deionized water. As shown in Figure [4](#F4){ref-type="fig"}a, the MR images enhanced by higher concentrations of UMFNPs appeared brighter than these of lower concentration. Furthermore, the T~1~-weighted MR images reveal that the Mn~0.75~Fe~2.25~O~4~ nanoparticles produce the highest signal intensity among the different Mn~x~Fe~3-x~O~4~ nanoparticles. Figure [4](#F4){ref-type="fig"}b shows the linear fit of the T~1~ relaxation times versus the \[Fe+Mn\] concentrations, the slope of which is the r~1~ relaxivity. The r~1~ relaxivity values and r~2~/r~1~ ratios for the different Mn~x~Fe~3-x~O~4~ nanoparticles are presented in Figure [4](#F4){ref-type="fig"}c and Table [S4](#SM0){ref-type="supplementary-material"}. The *in vitro* T~1~ contrast abilities of the 3 nm Mn~x~Fe~3-x~O~4~ nanoparticles improve with increasing Mn-doping levels up to x = 0.75 and then decline as the Mn doping level is further increased. The maximum r~1~ relaxivity is 10.35 mM^-1^s^-1^ and was obtained with the Mn~0.75~Fe~2.25~O~4~ nanoparticles, while the Mn~1.23~Fe~1.77~O~4~ nanoparticles exhibit the smallest r~2~/r~1~ ratio of 2.29 at 3 T. The results obtained from the relaxometric measurements demonstrating that ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles (x = 0.75- 1.23) are good candidates as T~1~ MRI contrast agents.

The mechanism of varied T~1~ relaxometric properties involved in the Mn~x~Fe~3-x~O~4~ nanoparticles is attributed to a combination of the inner-sphere and outer-sphere contributions [@B34]. While water molecules directly coordinated to the surface ions of the nanoparticles are responsible for the inner-sphere relaxation contribution, the spin-spin interactions between the nanoparticles and the water molecules in the nearby environment affect the outer-sphere relaxation. The contrast enhancement of individual contrast agents is thus determined by both their chemical composition and magnetic properties. For T~1~ contrast agents, in accordance with the classical Solomon-Bloembergen-Morgan (SBM) theory [@B33], the T~1~ relaxivity can be given by [@B13]:

Where ρ is the density of the Mn~x~Fe~3-x~O~4~ nanoparticles; γ~I~ is the gyromagnetic constant for proton; Mn is the molar mass; L refers to the thickness of surface impermeable molecule layer; Ms is the saturation magnetization of the UMFNPs; a is the particles core radius; D is the water diffusion coefficient; The translational diffusion time τ~D~ can be expressed as τ~D~ = r^2^/D; r equal to the a plus L; J~A~ is the Ayant\'s spectral density function; P~M~ is the molar fraction of the metal ions on the surface; q is the number of water molecules bound per metal ion; and τ~M~ is the residence lifetime of the bound water.

Mn~x~Fe~3-x~O~4~ nanoparticles possessing higher saturation magnetizations (Ms) result in larger r~1~ relaxivities due to the increased outer-sphere contribution. The inner-sphere contribution increases with the increasing Mn^2+^-doping level in the Mn~x~Fe~3-x~O~4~ nanoparticles due to the small τ~M~ of Mn(H~2~O)~6~^2+^, which is 100 times smaller than that of Fe(H~2~O)~6~^3+^ [@B33]. The overall T~1~ relaxivity of a Mn~x~Fe~3-x~O~4~ nanoparticle with a certain Mn-doping level is the sum of its inner-sphere and outer-sphere contributions.

*In Vivo* MR Imaging
--------------------

To evaluate the MRI imaging efficiency of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles *in vivo*, Balb/c mice were used for liver-specific contrast-enhanced MRI. The samples were intravenously administrated. The experimental dose was set as 3 mg \[Fe+Mn\] per kilogram mouse body weight. T~1~ images at transverse of the liver was acquired at 0, 3, 10, 30, 60, 90, 120, and 180 min post-injection of the Mn~x~Fe~3-x~O~4~ nanoparticles (Figure [5](#F5){ref-type="fig"}a). Significant signal enhancement in the T~1~-weighted MR images can be observed, demonstrating that these Mn~x~Fe~3-x~O~4~ nanoparticles can effectively accumulate in the liver. Figure [5](#F5){ref-type="fig"}b shows the MR signal changes in the T~1~-weighted MR images of the liver at different time points. The MR signal intensity changes were quantified using ΔSNR as calculated from the following equations:
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where SI stands for the signal intensity and SD stands for the standard deviation [@B35].

The highestΔSNR values of the contrast-enhanced MR images of the liver are 40.1 ± 2.3%, 48.4 ± 3.2%, 73.1 ± 1.4%, 71.6 ± 3.2%, 73.8 ± 2.7%, and 82.2 ± 2.1%, which occurred at 30 min post-injection of the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~, MnFe~2~O~4~, Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles, respectively. The ΔSNRs increase linearly with the increasing Mn-doping levels, revealing that the *in vivo* contrast abilities in the liver of these Mn~x~Fe~3-x~O~4~ nanoparticles strongly depend on their Mn-doping level. In addition, the Mn~0.75~Fe~2.25~O~4~ nanoparticles, which were expected to show a relatively large ΔSNR due to their high r~1~ relaxivity of 10.36 mM^-1^s^-1^, show a relatively small ΔSNR of 73.1%. The maximum ΔSNR of 82.2% was obtained using the Mn~1.57~Fe~1.43~O~4~ nanoparticles, which have a relatively low r~1~ relaxivity of 7.66 mM^-1^s^-1^, which suggests that the *in vivo* contrast ability can be affected by both the T~1~ relaxivities and the nano-bio interactions of Mn~x~Fe~3-x~O~4~ nanoparticles.

Pharmacokinetics and biodistribution of the Mn~x~Fe~3-x~O~4~ nanoparticles
--------------------------------------------------------------------------

The pharmacokinetics and biodistribution of the Mn~x~Fe~3-x~O~4~ nanoparticles were then carried out to understand the effects of their *in vivo* behavior on the contrast efficacy. Figure [6](#F6){ref-type="fig"}a presents the concentration of the \[Fe+Mn\] levels in the blood after injection of the Mn~x~Fe~3-x~O~4~ nanoparticles *via* tail vein. All the curves showed biexponential characteristics [@B36]. Several of the key pharmacokinetic parameters, including the distribution half-life (t~1/2α~), elimination half-life (t~1/2β~), and clearance (CL), are summarized in Table [S5](#SM0){ref-type="supplementary-material"}. The distribution half-life (t~1/2α~) are 0.64, 0.62, 0.53, 0.50, 0.34 and 0.17 h for the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~, MnFe~2~O~4~, Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles, respectively. The elimination half-life (t~1/2β~) are 8.01, 9.59, 10.03, 10.56, 12.7 and 17.29 h for the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~, MnFe~2~O~4~, Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles, respectively. Increasing the Mn-doping concentration reduces the distribution half-life time and improves the elimination half-life time. Clearance (CL) [@B37]-[@B39] is a parameter used to measure the efficiency of the body toward eliminating particles through excretory or metabolic pathways. CL for Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~, MnFe~2~O~4~, Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles were found to be 1, 0.67, 0.42, 0.48, 0.41 and 0.26 mL/h, respectively. As shown in Figure [6](#F6){ref-type="fig"}b, the CL declined with the increase of the Mn-doping concentration. This decrease in CL rate is consistent with the increase in the elimination half-life, indicating a reduced efficiency of the body toward eliminating the particles. These results explicitly suggest a dependence of half-life time and elimination on the Mn-doping level for the Mn~x~Fe~3-x~O~4~ nanoparticles. Figure [6](#F6){ref-type="fig"}c and d shows the biodistributions of the Mn~x~Fe~3-x~O~4~ nanoparticles at 3 h and 24 h postinjection. The results indicate that the Mn~x~Fe~3-x~O~4~ nanoparticles mainly accumulate in the liver, spleen and kidney after 3 h, while the accumulation of Mn~x~Fe~3-x~O~4~ nanoparticles in the liver is reduced after 24 h. The accumulation of Mn~1.57~Fe~1.43~O~4~ nanoparticles in the liver is much higher than that of the other Mn~x~Fe~3-x~O~4~ nanoparticles, suggesting that Mn~x~Fe~3-x~ O~4~ nanoparticles with high-Mn doping concentrations can efficiently accumulate in the liver. Early studies have revealed that hepatocytes can uptake the Mn^2+^ *via* vitamin B~6~ transporters selectively [@B40]. Our previous work [@B7] has also proven that the accumulation of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles in the liver can be attributed to hepatocyte-specific uptake, while traditional superparamagnetic iron oxide nanoparticles were mostly localized in Kupffer cells. Therefore, it is reasonable to believe that the Mn^2+^ concentration on the surface of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles plays a significant role in its accumulation in the liver due to hepatocyte-specific uptake, although the detailed molecular mechanism still needs to be revealed. The accumulation amounts of the Mn~x~Fe~3-x~O~4~ nanoparticles in the liver correspond well to their respective ΔSNRs in the liver, indicating that the *in vivo* contrast ability is determined by the *in vivo* accumulation of the nanoparticles rather than their *in vitro* r~1~ relaxivity in this case.

*In Vitro* and *In Vivo* Biosafety Evaluation
---------------------------------------------

To assess the biosafety of the Mn~x~Fe~3-x~O~4~ nanoparticles, *in vitro* cell cytotoxicity assays, *in vivo* blood routine examination, blood biochemistry test and H&E staining examination were conducted using Balb/c mice. A cck-8 colorimetric assay using Chang liver cells and HepG2 cells were performed to evaluate the cytotoxicity of the UMFNPs (Figure [7](#F7){ref-type="fig"}). The viabilities of the Chang liver cells exceed 80% at a high \[Fe+Mn\] concentration of 150 µg/mL for the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~ and Mn~0.75~Fe~2.25~O~4~ nanoparticles after incubating for 24 h. In contrast, the viabilities of the Chang liver cells are less than 70% at \[Fe+Mn\] concentrations higher than 50 µg/mL for the Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles after incubating for 24 h. These results indicate that ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles with high Mn-doping levels (x = 1.23 and 1.57) can induce significant cytotoxicity in Chang liver cells. Similar results were observed in HepG2 cells. The viabilities of HepG2 cells are higher than 80% at a high \[Fe+Mn\] concentration of 150 µg/mL for the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~ and Mn~0.75~Fe~2.25~O~4~ nanoparticles, while the viabilities of HepG2 cells decreased to 50% at a \[Fe+Mn\] concentration of only 50 µg/mL for the Mn~1.57~Fe~1.43~O~4~ nanoparticles. For the *in vivo* biosafety investigation, mice were intravenously injected with Mn~x~Fe~3-x~O~4~ nanoparticles at a dosage of 3 mg \[Fe+Mn\]/kg. After a 24 h circulation time, the whole blood, serum and liver were obtained for the blood routine examination, blood biochemistry tests and H&E staining examinations, respectively. Figure [8](#F8){ref-type="fig"}a-h shows the blood routine examination results of the Mn~x~Fe~3-x~O~4~ nanoparticles, including values for the red blood cells (RBC), hemoglobin (HGB), white blood cells (WBC), hematocrit (HCT), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets (PLT) and mean corpuscular volume (MCV). These markers are within the normal range without any observable difference from those of the mice in the control group, suggesting good hemocompatibility for the Mn~x~Fe~3-x~O~4~ nanoparticles. For the blood biochemistry tests, important hepatic function indicators, such as the alanine transferase (ALT), aspartate transferase (AST), total protein (TP), albumin (ALB), total biliary acid (TBA), direct bilirubin (DBIL) and alkaline phosphatase (ALP) values, were investigated. As shown in Figure [8](#F8){ref-type="fig"}i-o, no significant difference in the levels of these markers compared to the control are observed for the Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~ and MnFe~2~O~4~ nanoparticles, indicating a good hepatic safety profile for these nanoparticles. However, the TBA and DBIL values of the Mn~1.23~Fe~1.77~O~4~ and Mn~1.57~Fe~1.43~O~4~ nanoparticles treated groups were much higher than those of the other Mn~x~Fe~3-x~O~4~ nanoparticles treated groups and the control group. Nanoparticles can be cleared through the liver into the bile, and the levels of TBA and DBIL reflect the liver functions of excretion, secretion and detoxification [@B41], [@B42]. The increased TBA and DBIL values imply a potential toxicity towards the functions of the liver caused by the increasing manganese content. The cellular internalization of Mn~x~Fe~3-x~O~4~ may trigger the partial dissolution of the nanoparticles, leading to the release of Mn ions. The toxicity of Mn ions results from the variable valence states of Mn and its disruption of the homeostasis of pro-oxidant and antioxidant factors, which leads to toxic damage [@B43], [@B44]. To further evaluate the potential tissue damage, inflammation or lesions in the liver that Mn~x~Fe~3-x~O~4~ nanoparticles may cause, H&E staining examinations were conducted. As shown in Figure [9](#F9){ref-type="fig"}, compared with those of the control group, the tissue structures of the livers from mice treated with Mn~x~Fe~3-x~O~4~ nanoparticles remain intact, and no abnormal changes in the pathological histology or cellular structures are observed in the livers after 1 day, indicating no obvious risks of the Mn~x~Fe~3-x~O~4~ nanoparticles toward the liver. These results suggest that Mn~0.32~Fe~2.68~O~4~, Mn~0.37~Fe~2.63~O~4~, Mn~0.75~Fe~2.25~O~4~ and MnFe~2~O~4~, which have insignificant toxicities, are suitable for *in vivo* MRI.

The chemical design of nanoparticle-based contrast agents is typically highly concentrated to maximize the relaxivity. However, the optimization of a single factor is insufficient to predict the *in vivo* contrast efficacy. The nano-bio interactions and *in vivo* safety should also be taken into account for maximizing the *in vivo* contrast efficacy. Based on the above experimental results, the Mn-doping level of Mn~x~Fe~3-x~O~4~ nanoparticles can simultaneously impact the *in vitro* T~1~ relaxivity, the accumulation of nanoparticles in the liver and the biosafety. The key correlations between the chemical composition and the *in vitro* T~1~ relaxivity, *in vivo* nano-bio interactions, and toxicity should be considered together. As shown in Figure [10](#F10){ref-type="fig"}, as the Mn-doping level increases, the T~1~ relaxivity initially increases to 10.36 mM^-1^s^-1^ (x = 0.75) and then gradually decreases to 7.66 mM^-1^s^-1^ (x = 1.57), and both the ∆SNR and the particle accumulation in the liver increased. However, the *in vitro* cell viability and the liver functions of excretion, secretion and detoxification are adversely impacted by an increase in the Mn-doping level. The comparison and correlation analysis suggest that Mn~x~Fe~3-x~O~4~ nanoparticles with Mn contents ranging from 0.75 to 1, have significantly improved*in vivo* contrast efficacies, and can be potential contrast agents for clinical liver-specific MRI.

Conclusions
===========

In summary, 3 nm Mn~x~Fe~3-x~O~4~ nanoparticles with tunable Mn-doping levels (x = 0.32, 0.37, 0.75, 1, 1.23 and 1.57) have been successfully synthesized *via* a DSTD method. These Mn~x~Fe~3-x~O~4~ nanoparticles were used as a model system to systematically investigate the correlation between chemical composition and *in vivo* T~1~ contrast efficacy. The results suggest that variations in the Mn contents of Mn~x~Fe~3-x~O~4~ nanoparticles can effectively impact *in vitro* T~1~ relaxivities, *in vivo* nano-bio interactions and toxicities simultaneously. The relationships between the chemical composition and each individual factor have been revealed. It was found that with increasing Mn-doping levels in the Mn~x~Fe~3-x~O~4~ nanoparticles, the T~1~ relaxivities initially increased and then declined, while the *in vivo* MR signals increased linearly, along with an adverse increase in their toxicities. A comparison analysis of these given relationships indicated that the Mn~x~Fe~3-x~O~4~ (x = 0.75-1) nanoparticles, as UFNP-based contrast agents, exhibited the optimal *in vivo* contrast efficacy for liver-specific MRI. The principles identified in this work and multiple factor assessment used herein can be applied to optimize other UFNPs for high- performance contrast-enhanced MRI. We believe this work represents an essential step towards the development of high-efficiency and low-toxicity UFNP-based contrast agents for both fundamental research and clinical translation.
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ALT

:   alanine transferase

ALP

:   alkaline phosphatase

ALB

:   albumin

AST

:   aspartate transferase

CL

:   clearance

DSTD

:   dynamic simultaneous thermal decomposition

DLS

:   dynamic light scattering

DBIL

:   direct bilirubin

HCT

:   hematocrit

HGB

:   hemoglobin

MRI

:   magnetic resonance imaging

MCH

:   mean corpuscular hemoglobin

MCHC

:   mean corpuscular hemoglobin concentration

MCV

:   mean corpuscular volume

PLT

:   platelets

RBC

:   red blood cells

SQUID

:   superconducting quantum interference device

TBA

:   total biliary acid

TEM

:   transmission electron microscopy

TP

:   total protein

UFNPs

:   ultrasmall ferrite nanoparticles

UMFNPs

:   ultrasmall manganese ferrite nanoparticles

WBC

:   white blood cell

XRD

:   X-ray powder diffraction

XPS

:   X-ray photoelectron spectroscopy.

![**(a-f)** TEM images of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. The insets are the high-resolution TEM images. **(g)** XRD patterns of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. XPS spectra of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles,**(h)** Fe 2p and **(i)** Mn 2p.](thnov09p1764g001){#F1}

![Magnetic characterization of 3 nm Mn~x~Fe~3-x~O~4~ nanoparticles. **(a)** Field-dependent magnetization curves (M-H) of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles at 300 K. **(b)** The magnetizations at 3 T of the ultrasmall Mn~x~Fe~3-x~O~4~ samples.](thnov09p1764g002){#F2}

![Hydrodynamic size of **(a)** MnFe~2~O~4~\@mPEG1000, **(b)** MnFe~2~O~4~\@mPEG2000, and **(c)** MnFe~2~O~4~\@mPEG5000 in water. The insets are digital photographs of the aqueous MnFe~2~O~4~ nanoparticles dispersions. **(d)**-**(f)** Time-dependent hydrodynamic size of ultrasmall MnFe~2~O~4~ nanoparticles modified with **(d)** mPEG1000, **(e)** mPEG2000 and **(f)** mPEG5000, respectively. **(g)** T~1~-weighted phantom imaging of ultrasmall MnFe~2~O~4~ nanoparticles with different phosphorylated mPEG. **(h)** T~1~ relaxation rate of the MnFe~2~O~4~ nanoparticles different PEG chain lengths at various \[Fe+Mn\] concentrations. **(i)** r~1~ value and r~2~/r~1~ ratio of MnFe~2~O~4~ nanoparticles as a function of the mPEG molecular weight.](thnov09p1764g003){#F3}

![MR contrast effects of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles upon changes in the Mn doping level. **(a)** T~1~-weighted images of Mn~x~Fe~3-x~O~4~ nanoparticles. **(b)** T~1~ relaxation rate of the Mn~x~Fe~3-x~O~4~ nanoparticles and **(c)** r~1~ relaxivities and r~2~/r~1~ ratio of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles.](thnov09p1764g004){#F4}

![*In vivo* MR imaging of UMFNPs. **(a)**T~1~-weighted MR images of liver at 0, 3, 10, 30, 60, 90, 120, and 180 min after intravenous injection of 3 nm Mn~x~Fe~3-x~O~4~ nanoparticles and **(b)** quantification analysis of MR T~1~ signals changes.](thnov09p1764g005){#F5}

![*In vivo* behaviors of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles as determined by measuring Mn levels with ICP-MS. **(a)** Blood circulation of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. The pharmacokinetics of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles followed the two-compartment model. **(b)** Correlation of elimination half-life and clearance of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. **(c, d)** Biodistribution of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles in Balb/c mice at **(c)** 3 h and **(d)** 24 h post injection.](thnov09p1764g006){#F6}

![Relative viabilities of **(a)** Chang liver cells and **(b)** HepG2 cells incubated with ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles at various concentrations using standard cck-8 colorimetric assays. Error bars = SEM; \* p \< 0.05; \*\* p \< 0.01; \*\*\* p \< 0.001. p value is used to statistically analyze difference among groups at the \[Fe+Mn\] concentration of 50 µg/mL.](thnov09p1764g007){#F7}

![*In vivo* biosafety assessment of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. **(a-h)** Routine blood analysis: **(a)** red blood cells (RBC), **(b)** hemoglobin (HGB), **(c)** white blood cell (WBC), **(d)** hematocrit (HCT), **(e)** mean corpuscular hemoglobin (MCH), **(f)** mean corpuscular hemoglobin concentration (MCHC), **(g)** platelets (PLT) and **(h)** mean corpuscular volume (MCV); **(i-o)** Blood biochemistry test: **(i)** alanine transferase (ALT), **(j)** aspartate transferase (AST), **(k)** total protein (TP), **(l)** albumin (ALB), **(m)** total biliary acid (TBA), **(n)** direct bilirubin (DBIL) and **(o)** alkaline phosphatase (ALP).](thnov09p1764g008){#F8}

![H&E stained images of the liver of the mice harvested from control group and treated groups at 1 days after intravenous injection of ultrasmall Mn~x~Fe~3-x~O~4~ nanoparticles. Scale bar = 100 nm.](thnov09p1764g009){#F9}

![The comparison and correlation analysis of Mn concentration with *in vitro* T~1~ relaxivity, *in vivo* nano-bio interactions and biosafety.](thnov09p1764g010){#F10}

###### 

Detailed Synthetic Parameters for Ultrasmall Mn~x~Fe~3-x~O~4~ Nanoparticles

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Samples                Fe- eruciate (g)   Mn- oleate\   Oleyl alcohol (g)   Oleic acid (g)   Benzyl\     Heating rate (℃/min)   Aging temperature (℃)
                                            (g)                                                Ether (g)                          
  ---------------------- ------------------ ------------- ------------------- ---------------- ----------- ---------------------- -----------------------
  Mn~0.32~Fe~2.68~O~4~   2.14               0.62          1.61                0.57             10          5                      260

  Mn~0.37~Fe~2.63~O~4~   1.82               0.62          1.61                0.57             10          5                      260

  Mn~0.75~Fe~2.25~O~4~   1.40               0.62          1.61                0.57             10          5                      260

  MnFe~2~O~4~            1.07               0.62          1.61                0.57             10          5                      260

  Mn~1.23~Fe~1.77~O~4~   1.07               0.93          1.61                0.57             10          5                      260

  Mn~1.57~Fe~1.43~O~4~   1.07               1.24          1.61                0.57             10          5                      260
  -------------------------------------------------------------------------------------------------------------------------------------------------------
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